Identification of the Major Human Liver Cytochrome P450 Isoform(s) Responsible for the Formation of the Primary Metabolites of Ziprasidone and Prediction of Possible Drug Interactions

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2000 Apr 20

PMID 10771452

Citations 31

Authors

C Prakash

A Kamel

D Cui

R D Whalen

J J Miceli

D Tweedie

Affiliations

Soon will be listed here.

Abstract

Aims: To identify the cytochrome P450 (CYP) isoform(s) responsible for the formation of the primary metabolite of ziprasidone (ziprasidone sulphoxide), to determine the kinetics of its formation and to predict possible drug interactions by investigating CYP isoform inhibition in an in vitro study.

Methods: In vitro metabolism of [14C]-ziprasidone was studied using human liver microsomes. The metabolites were identified using mass spectrometry. The kinetics of metabolite formation were determined using [14C]-ziprasidone (10-200 microM) over 5 min, and Km and Vmax were estimated from Lineweaver-Burk plots. IC50 values for the inhibition of specific probe substrates for CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, by ziprasidone, risperidone and 9-hydroxyrisperidone were also determined using human liver microsomes from three subjects. Mean Ki values were calculated.

Results: Three CYP-mediated metabolites - ziprasidone sulphoxide, ziprasidone sulphone and oxindole acetic acid - were identified. The apparent Km and Vmax values for the formation of the major metabolite, ziprasidone sulphoxide (measured as the sum of sulphoxide and sulphone) were 235 microM and 1.14 nmol mg(-1) protein min(-1), respectively. Isoform-selective inhibitors and recombinant enzymes indicated that CYP3A4 is responsible for the formation of ziprasidone metabolites. Ziprasidone was not a substrate for the other isoforms studied. Similar in vitro inhibition of CYP2D6 (Ki 6.9-16 microM) and CYP3A4 (Ki 64-80 microM) was obtained with ziprasidone, risperidone and 9-hydroxyrisperidone. The in vivo free drug concentrations associated with clinically effective doses of ziprasidone are at least 1500-fold lower than the mean Ki for either CYP2D6 inhibition or CYP3A4 inhibition.

Conclusions: Ziprasidone is predominantly metabolized by CYP3A4 in human liver microsomes and is not expected to mediate drug interactions with coadministered CYP substrates, at clinically effective doses.

Citing Articles

Precision Medicine into Clinical Practice: A Web-Based Tool Enables Real-Time Pharmacogenetic Assessment of Tailored Treatments in Psychiatric Disorders.

Zampatti S, Fabrizio C, Ragazzo M, Campoli G, Caputo V, Strafella C J Pers Med. 2021; 11(9).

PMID: 34575628 PMC: 8471120. DOI: 10.3390/jpm11090851.

In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions.

Wojcikowski J, Danek P, Basinska-Ziobron A, Puklo R, Daniel W Pharmacol Rep. 2020; 72(3):612-621.

PMID: 32219694 PMC: 7329795. DOI: 10.1007/s43440-020-00089-z.

Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure.

Kiss A, Menus A, Toth K, Deri M, Sirok D, Gabri E Eur Arch Psychiatry Clin Neurosci. 2019; 270(1):71-82.

PMID: 30604050 DOI: 10.1007/s00406-018-0975-2.

In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone.

Giri P, Gupta L, Naidu S, Joshi V, Patel N, Giri S Drug Metab Lett. 2018; 12(2):101-116.

PMID: 30117405 PMC: 6416464. DOI: 10.2174/1872312812666180816164626.

Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.

Mauri M, Paletta S, Di Pace C, Reggiori A, Cirnigliaro G, Valli I Clin Pharmacokinet. 2018; 57(12):1493-1528.

PMID: 29915922 DOI: 10.1007/s40262-018-0664-3.

References

Sonderfan A, Arlotto M, Dutton D, McMillen S, Parkinson A . Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch Biochem Biophys. 1987; 255(1):27-41. DOI: 10.1016/0003-9861(87)90291-8. View

Miners J, Smith K, Robson R, McManus M, Veronese M, Birkett D . Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol. 1988; 37(6):1137-44. DOI: 10.1016/0006-2952(88)90522-9. View

Gonzalez F . The molecular biology of cytochrome P450s. Pharmacol Rev. 1988; 40(4):243-88. View

Smith P, Krohn R, Hermanson G, Mallia A, Gartner F, Provenzano M . Measurement of protein using bicinchoninic acid. Anal Biochem. 1985; 150(1):76-85. DOI: 10.1016/0003-2697(85)90442-7. View

Meier U, Kronbach T, Meyer U . Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Anal Biochem. 1985; 151(2):286-91. DOI: 10.1016/0003-2697(85)90177-0. View

Kronbach T . Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6. Methods Enzymol. 1991; 206:509-17. DOI: 10.1016/0076-6879(91)06120-r. View

Nelson D, Kamataki T, Waxman D, Guengerich F, Estabrook R, Feyereisen R . The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 1993; 12(1):1-51. DOI: 10.1089/dna.1993.12.1. View

Tucker G . The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol. 1992; 30(11):550-3. View

Peck C, Temple R, Collins J . Understanding consequences of concurrent therapies. JAMA. 1993; 269(12):1550-2. View

10.

Tassaneeyakul W, Birkett D, Veronese M, McManus M, Tukey R, Quattrochi L . Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther. 1993; 265(1):401-7. View

11.

Brosen K, Hansen J, Nielsen K, Sindrup S, Gram L . Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol. 1993; 44(4):349-55. DOI: 10.1007/BF00316471. View

12.

Huang M, Van Peer A, Woestenborghs R, De Coster R, Heykants J, JANSEN A . Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993; 54(3):257-68. DOI: 10.1038/clpt.1993.146. View

13.

Wrighton S, Vandenbranden M, Stevens J, Shipley L, Ring B, Rettie A . In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev. 1993; 25(4):453-84. DOI: 10.3109/03602539308993982. View

14.

Rodrigues A . Use of in vitro human metabolism studies in drug development. An industrial perspective. Biochem Pharmacol. 1994; 48(12):2147-56. DOI: 10.1016/0006-2952(94)00312-2. View

15.

Newton D, Wang R, Lu A . Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos. 1995; 23(1):154-8. View

16.

Ring B, Binkley S, Roskos L, Wrighton S . Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1'-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther. 1995; 275(3):1131-5. View

17.

Prakash C, Kamel A, Anderson W, Howard H . Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone. Drug Metab Dispos. 1997; 25(2):206-18. View

18.

Omura T, Sato R . THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. J Biol Chem. 1964; 239:2370-8. View

19.

Wilner K, Demattos S, Anziano R, Apseloff G, Gerber N . Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers. Br J Clin Pharmacol. 2000; 49 Suppl 1:43S-47S. PMC: 2015060. DOI: 10.1046/j.1365-2125.2000.00152.x. View

20.

Wilner K, Hansen R, Folger C, Geoffroy P . The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. Br J Clin Pharmacol. 2000; 49 Suppl 1:57S-60S. PMC: 2015049. DOI: 10.1046/j.1365-2125.2000.00154.x. View